{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T04:39:57Z","timestamp":1792557597720,"version":"4.5.0"},"reference-count":76,"publisher":"Journal of Neurosurgery Publishing Group (JNSPG)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>The aim of this study was to report the treatment course of histologically confirmed metastases to the pituitary gland (pituitary metastasis).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>The Mayo data explorer was used to find patients with pituitary metastasis. Twenty-one patients were identified between the years 2001 and 2021, and their data were retrospectively collected.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>The most common primary cancer origin was lung in men (45%) and breast in women (33%). The median age was 66 years (IQR 56\u201368 years). Patients presented with headache (67% [14\/21]), vision problems (86% [18\/21]), anterior hypopituitarism (71% [15\/21]), and arginine vasopressin deficiency (38% [8\/21]). Pituitary metastases were found before the diagnosis of the primary cancer in 5 patients (24%). The mean \u00b1 SD tumor size was 2.0 \u00b1 0.7 cm, and 90% (19\/21) presented as a solitary pituitary mass with no other intracranial metastatic lesions. Common radiological features were pituitary stalk thickening (90% [19\/21]), cavernous sinus involvement (71% [15\/21]), and constriction at the diaphragma sellae (52% [11\/21]). Transsphenoidal surgery was performed in 20 patients, and subtotal resection was most frequently attained (76% [16\/21]). Fourteen patients (67%) had adjuvant radiation therapy, and 15 patients (71%) were treated with systemic therapy. The median time from surgery to the initiation of radiation therapy was 16 days (IQR 11\u201321 days), and that from surgery to the initiation of systemic therapy was 5.0 months (IQR 1.5\u201314 months). During management, headaches improved in 57% (8\/14) and vision problems improved in 61% (11\/18) of cases; new hypopituitarism occurred in 5 patients. Six patients developed recurrence, and the median progression-free survival was 24 months (95% CI 5.4\u201343 months). After recurrence, 1 patient with adenoid cystic carcinoma was treated with rescue radiotherapy twice, and 4 patients responded well to systemic therapy. The median overall survival (OS) was 25 months (95% CI 7.1\u201343 months). The mean OS was better in patients with neuroendocrine lung tumor (261 months) and papillary thyroid carcinoma (80 months) and worse in patients with small cell lung cancer (4 months) and unknown origin (5 months).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>Surgery with or without adjuvant radiotherapy is effective for mass reduction, rapid symptomatic improvement of vision and headaches, and definitive diagnosis. Even after local tumor control failure, some patients still benefit from radiation and\/or systemic therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3171\/2023.5.focus23185","type":"journal-article","created":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T07:20:19Z","timestamp":1690874419000},"page":"E13","source":"Crossref","is-referenced-by-count":14,"title":["Treatment outcome of metastasis to the pituitary gland: a case series of 21 patients with pathological diagnosis"],"prefix":"10.3171","volume":"55","author":[{"given":"Sukwoo","family":"Hong","sequence":"first","affiliation":[{"name":"Department of Neurological Surgery,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John L.","family":"Atkinson","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Erickson","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Metabolism and Nutrition,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sani H.","family":"Kizilbash","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason T.","family":"Little","sequence":"additional","affiliation":[{"name":"Department of Radiology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Routman","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie J.","family":"Van Gompel","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery,"},{"name":"Department of Otolaryngology,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1754","reference":[{"issue":"1","key":"b1","series-title":"J Neurooncol","first-page":"175","article-title":"Stereotactic radiosurgery for pituitary and cavernous sinus metastases","volume":"161","author":"Lin YY","year":"2023","unstructured":"Lin YY, Wu HM, Yang HC,  Stereotactic radiosurgery for pituitary and cavernous sinus metastases. J Neurooncol. 2023;161(1):175\u2013184.36617600"},{"issue":"5","key":"b2","series-title":"Oncologist","first-page":"e789","article-title":"Extended survival after surgical resection for pituitary metastases: clinical features, management, and outcomes of metastatic disease to the sella","volume":"25","author":"Patel KR","year":"2020","unstructured":"Patel KR, Zheng J, Tabar V, Cohen MA, Girotra M. Extended survival after surgical resection for pituitary metastases: clinical features, management, and outcomes of metastatic disease to the sella. Oncologist. 2020;25(5):e789\u2013e797."},{"issue":"8","key":"b3","series-title":"J Clin Endocrinol Metab","first-page":"3379","article-title":"Pituitary metastases: a nationwide study on current characteristics with special reference to breast cancer","volume":"104","author":"Schill F","year":"2019","unstructured":"Schill F, Nilsson M, Olsson DS,  Pituitary metastases: a nationwide study on current characteristics with special reference to breast cancer. J Clin Endocrinol Metab. 2019;104(8):3379\u20133388."},{"key":"b4","series-title":"World Neurosurg","first-page":"122","article-title":"Diagnosis, therapy, and therapeutic effects in cases of pituitary metastasis","volume":"117","author":"Zhao Y","year":"2018","unstructured":"Zhao Y, Lian W, Xing B,  Diagnosis, therapy, and therapeutic effects in cases of pituitary metastasis. World Neurosurg. 2018;117:122\u2013128.29883826"},{"issue":"4","key":"b5","series-title":"J Neurosurg","first-page":"998","article-title":"Pituitary metastases: current practice in Japan","volume":"123","author":"Habu M","year":"2015","unstructured":"Habu M, Tokimura H, Hirano H,  Pituitary metastases: current practice in Japan. J Neurosurg. 2015;123(4):998\u20131007.26186025"},{"issue":"2","key":"b6","series-title":"World Neurosurg","first-page":"327","article-title":"Pituitary metastases: role of surgery","volume":"79","author":"Zoli M","year":"2013","unstructured":"Zoli M, Mazzatenta D, Faustini-Fustini M, Pasquini E, Frank G. Pituitary metastases: role of surgery. World Neurosurg. 2013;79(2):327\u2013330.22480977"},{"issue":"1","key":"b7","series-title":"J Neurosurg","first-page":"69","article-title":"Symptomatic pituitary metastases","volume":"89","author":"Morita A","year":"1998","unstructured":"Morita A, Meyer FB, Laws ER Jr. Symptomatic pituitary metastases. J Neurosurg. 1998;89(1):69\u201373.9647174"},{"issue":"1","key":"b8","series-title":"J Neurol Neurosurg Psychiatry","first-page":"44","article-title":"Presentation and management of parasellar and suprasellar metastatic mass lesions","volume":"48","author":"Kattah JC","year":"1985","unstructured":"Kattah JC, Silgals RM, Manz H, Toro JG, Dritschilo A, Smith FP. Presentation and management of parasellar and suprasellar metastatic mass lesions. J Neurol Neurosurg Psychiatry. 1985;48(1):44\u201349.3973620"},{"issue":"4","key":"b9","series-title":"Neurosurg Focus","first-page":"E8","article-title":"Metastases to the pituitary gland","volume":"16","author":"Fassett DR","year":"2004","unstructured":"Fassett DR, Couldwell WT. Metastases to the pituitary gland. Neurosurg Focus. 2004;16(4):E8."},{"issue":"8","key":"b10","series-title":"Neurology","first-page":"998","article-title":"Pituitary metastasis: incidence in cancer patients and clinical differentiation from pituitary adenoma","volume":"31","author":"Max MB","year":"1981","unstructured":"Max MB, Deck MD, Rottenberg DA. Pituitary metastasis: incidence in cancer patients and clinical differentiation from pituitary adenoma. Neurology. 1981;31(8):998\u20131002.7196526"},{"issue":"5","key":"b11","series-title":"J Clin Endocrinol Metab","first-page":"1812","article-title":"Pituitary stalk lesions: the Mayo Clinic experience","volume":"98","author":"Turcu AF","year":"2013","unstructured":"Turcu AF, Erickson BJ, Lin E,  Pituitary stalk lesions: the Mayo Clinic experience. J Clin Endocrinol Metab. 2013;98(5):1812\u20131818."},{"issue":"1","key":"b12","series-title":"Radiology","first-page":"181","article-title":"Screening for cerebral metastases with FDG PET in patients undergoing whole-body staging of non-central nervous system malignancy","volume":"226","author":"Rohren EM","year":"2003","unstructured":"Rohren EM, Provenzale JM, Barboriak DP, Coleman RE. Screening for cerebral metastases with FDG PET in patients undergoing whole-body staging of non-central nervous system malignancy. Radiology. 2003;226(1):181\u2013187.12511688"},{"key":"b13","series-title":"American Cancer Society","article-title":"Lung cancer survival rates","unstructured":"Lung cancer survival rates. American Cancer Society. Updated March 2, 2022. Accessed February 21, 2023.https:\/\/www.cancer.org\/cancer\/lung-cancer\/detection-diagnosis-staging\/survival-rates.html"},{"key":"b14","series-title":"FDA.gov","article-title":"FDA approves durvalumab for extensive-stage small cell lung cancer","unstructured":"FDA approves durvalumab for extensive-stage small cell lung cancer. FDA.gov. Updated March 30, 2020. Accessed June 22, 2023.https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-durvalumab-extensive-stage-small-cell-lung-cancer"},{"issue":"1","key":"b15","series-title":"Lancet Oncol","first-page":"51","article-title":"Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial","volume":"22","author":"Goldman JW","year":"2021","unstructured":"Goldman JW, Dvorkin M, Chen Y,  Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2021;22(1):51\u201365.33285097"},{"issue":"3","key":"b16","series-title":"Lancet Oncol","first-page":"239","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell R","year":"2012","unstructured":"Rosell R, Carcereny E, Gervais R,  Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13(3):239\u2013246.22285168"},{"key":"b17","series-title":"Genentech","article-title":"FDA approves first personalized medicine for egfr mutation-positive metastatic non-small cell lung cancer in the United States","unstructured":"FDA approves first personalized medicine for egfr mutation-positive metastatic non-small cell lung cancer in the United States. Genentech. Updated March 14, 2013. Accessed June 22, 2023.https:\/\/www.gene.com\/media\/news-features\/tarceva-approval-nsclc#:~:text=May%2014th%2C%202013,by%20an%20FDA%2Dapproved%20test"},{"issue":"20","key":"b18","series-title":"Clin Cancer Res","first-page":"5130","article-title":"Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity","volume":"22","author":"Ballard P","year":"2016","unstructured":"Ballard P, Yates JW, Yang Z,  Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity. Clin Cancer Res. 2016;22(20):5130\u20135140.27435396"},{"key":"b19","series-title":"FDA.gov","article-title":"FDA approves osimertinib as adjuvant therapy for non-small cell lung cancer with EGFR mutations","unstructured":"FDA approves osimertinib as adjuvant therapy for non-small cell lung cancer with EGFR mutations. FDA.gov. Updated December 18, 2020. Accessed June 22, 2023.https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-osimertinib-adjuvant-therapy-non-small-cell-lung-cancer-egfr-mutations"},{"issue":"2","key":"b20","series-title":"N Engl J Med","first-page":"113","article-title":"Osimertinib in untreated EGFR-mutated advanced non\u2013small-cell lung cancer","volume":"378","author":"Soria JC","year":"2018","unstructured":"Soria JC, Ohe Y, Vansteenkiste J,  Osimertinib in untreated EGFR-mutated advanced non\u2013small-cell lung cancer. N Engl J Med. 2018;378(2):113\u2013125.29151359"},{"issue":"32","key":"b21","series-title":"J Clin Oncol","first-page":"3259","article-title":"National Cancer Institute Breast Cancer Steering Committee Working Group Report on Meaningful and Appropriate End Points for Clinical Trials in Metastatic Breast Cancer","volume":"36","author":"Seidman AD","year":"2018","unstructured":"Seidman AD, Bordeleau L, Fehrenbacher L,  National Cancer Institute Breast Cancer Steering Committee Working Group Report on Meaningful and Appropriate End Points for Clinical Trials in Metastatic Breast Cancer. J Clin Oncol. 2018;36(32):3259\u20133268."},{"issue":"12","key":"b22","series-title":"PLoS Med","first-page":"e1002201","article-title":"Mutational profile of metastatic breast cancers: a retrospective analysis","volume":"13","author":"Lefebvre C","year":"2016","unstructured":"Lefebvre C, Bachelot T, Filleron T,  Mutational profile of metastatic breast cancers: a retrospective analysis. PLoS Med. 2016;13(12):e1002201.28027327"},{"issue":"1","key":"b23","series-title":"NPJ Breast Cancer","first-page":"80","article-title":"Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups","volume":"7","author":"Johnston S","year":"2021","unstructured":"Johnston S, O\u2019Shaughnessy J, Martin M,  Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups. NPJ Breast Cancer. 2021;7(1):80.34158513"},{"key":"b24","article-title":"FDA approves new treatment for certain advanced or metastatic breast cancers","unstructured":"FDA approves new treatment for certain advanced or metastatic breast cancers. Accessed June 22, 2023.https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-treatment-certain-advanced-or-metastatic-breast-cancers"},{"key":"b25","series-title":"National Cancer Institute","article-title":"Breast cancer treatment (PDQ\u00ae)\u2013Health professional version","unstructured":"Breast cancer treatment (PDQ\u00ae)\u2013Health professional version. National Cancer Institute. Accessed June 22, 2023.https:\/\/www.cancer.gov\/types\/breast\/hp\/breast-treatment-pdq#_1452"},{"issue":"7","key":"b26","series-title":"N Engl J Med","first-page":"597","article-title":"Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer","volume":"382","author":"Murthy RK","year":"2020","unstructured":"Murthy RK, Loi S, Okines A,  Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med. 2020;382(7):597\u2013609.31825569"},{"key":"b27","series-title":"Drugs.com","article-title":"FDA approves Sutent for gastrointestinal stromal tumors and advanced renal cell carcinoma","unstructured":"FDA approves Sutent for gastrointestinal stromal tumors and advanced renal cell carcinoma. Drugs.com. Updated January 2006. Accessed June 22, 2023.https:\/\/www.drugs.com\/newdrugs\/fda-approves-sutent-gastrointestinal-stromal-tumors-advanced-renal-cell-carcinoma-389.html"},{"issue":"6C","key":"b28","series-title":"Anticancer Res","first-page":"4255","article-title":"Brain metastasis in renal cell cancer responding to sunitinib","volume":"27","author":"Koutras AK","year":"2007","unstructured":"Koutras AK, Krikelis D, Alexandrou N, Starakis I, Kalofonos HP. Brain metastasis in renal cell cancer responding to sunitinib. Anticancer Res. 2007;27(6C):4255\u20134257.18214028"},{"key":"b29","series-title":"FDA.gov","article-title":"FDA approves nivolumab plus cabozantinib for advanced renal cell carcinoma","unstructured":"FDA approves nivolumab plus cabozantinib for advanced renal cell carcinoma. FDA.gov. Updated January 22, 2021. Accessed June 22, 2023.https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-nivolumab-plus-cabozantinib-advanced-renal-cell-carcinoma"},{"issue":"9","key":"b30","series-title":"N Engl J Med","first-page":"829","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri TK","year":"2021","unstructured":"Choueiri TK, Powles T, Burotto M,  Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2021;384(9):829\u2013841.33657295"},{"issue":"14","key":"b31","series-title":"N Engl J Med","first-page":"1289","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer R","year":"2021","unstructured":"Motzer R, Alekseev B, Rha SY,  Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med. 2021;384(14):1289\u20131300."},{"key":"b32","series-title":"FDA.gov","article-title":"FDA approves lenvatinib plus pembrolizumab for advanced renal cell carcinoma","unstructured":"FDA approves lenvatinib plus pembrolizumab for advanced renal cell carcinoma. FDA.gov. Updated August 11, 2021. Accessed June 22, 2023.https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-lenvatinib-plus-pembrolizumab-advanced-renal-cell-carcinoma"},{"issue":"11","key":"b33","series-title":"Head Neck","first-page":"2407","article-title":"Survival and prognosis of metastatic head and neck adenoid cystic carcinoma","volume":"44","author":"Zhang D","year":"2022","unstructured":"Zhang D, Chai Y, Wei Y, Qi F, Dong M. Survival and prognosis of metastatic head and neck adenoid cystic carcinoma. Head Neck. 2022;44(11):2407\u20132416.35822446"},{"issue":"8","key":"b34","series-title":"Int J Oral Maxillofac Surg","first-page":"923","article-title":"Clinicopathological study of distant metastases of salivary adenoid cystic carcinoma","volume":"42","author":"Gao M","year":"2013","unstructured":"Gao M, Hao Y, Huang MX,  Clinicopathological study of distant metastases of salivary adenoid cystic carcinoma. Int J Oral Maxillofac Surg. 2013;42(8):923\u2013928.23706387"},{"issue":"35","key":"b35","series-title":"Oncotarget","first-page":"37117","article-title":"Adenoid cystic carcinoma: current therapy and potential therapeutic advances based on genomic profiling","volume":"6","author":"Chae YK","year":"2015","unstructured":"Chae YK, Chung SY, Davis AA,  Adenoid cystic carcinoma: current therapy and potential therapeutic advances based on genomic profiling. Oncotarget. 2015;6(35):37117\u201337134.26359351"},{"key":"b36","series-title":"Cancer.net","article-title":"Thyroid cancer: statistics","unstructured":"Thyroid cancer: statistics. Cancer.net. Updated March, 2022. Accessed June 22, 2023.https:\/\/www.cancer.net\/cancer-types\/thyroid-cancer\/statistics#:~:text=If%20there%20is%20distant%20spread,%2C%20the%20rate%20is%2063%25"},{"key":"b37","series-title":"Cancer Current Events Blog","article-title":"FDA approves lenvatinib for radioactive iodine-refractory thyroid cancer","unstructured":"FDA approves lenvatinib for radioactive iodine-refractory thyroid cancer. Cancer Current Events Blog. National Cancer Institute. March 2, 2015. Accessed June 22, 2023.https:\/\/www.cancer.gov\/news-events\/cancer-currents-blog\/2015\/fda-approves-lenvima"},{"issue":"10","key":"b38","series-title":"J Natl Cancer Inst","first-page":"1021","article-title":"The Molecular Analysis for Therapy Choice (NCI-MATCH) trial: lessons for genomic trial design","volume":"112","author":"Flaherty KT","year":"2020","unstructured":"Flaherty KT, Gray R, Chen A,  The Molecular Analysis for Therapy Choice (NCI-MATCH) trial: lessons for genomic trial design. J Natl Cancer Inst. 2020;112(10):1021\u20131029.31922567"},{"issue":"1","key":"b1","series-title":"J Neurooncol","first-page":"175","article-title":"Stereotactic radiosurgery for pituitary and cavernous sinus metastases","volume":"161","author":"Lin YY","year":"2023","unstructured":"Lin YY, Wu HM, Yang HC,  Stereotactic radiosurgery for pituitary and cavernous sinus metastases. J Neurooncol. 2023;161(1):175\u2013184.36617600"},{"issue":"5","key":"b2","series-title":"Oncologist","first-page":"e789","article-title":"Extended survival after surgical resection for pituitary metastases: clinical features, management, and outcomes of metastatic disease to the sella","volume":"25","author":"Patel KR","year":"2020","unstructured":"Patel KR, Zheng J, Tabar V, Cohen MA, Girotra M. Extended survival after surgical resection for pituitary metastases: clinical features, management, and outcomes of metastatic disease to the sella. Oncologist. 2020;25(5):e789\u2013e797."},{"issue":"8","key":"b3","series-title":"J Clin Endocrinol Metab","first-page":"3379","article-title":"Pituitary metastases: a nationwide study on current characteristics with special reference to breast cancer","volume":"104","author":"Schill F","year":"2019","unstructured":"Schill F, Nilsson M, Olsson DS,  Pituitary metastases: a nationwide study on current characteristics with special reference to breast cancer. J Clin Endocrinol Metab. 2019;104(8):3379\u20133388."},{"key":"b4","series-title":"World Neurosurg","first-page":"122","article-title":"Diagnosis, therapy, and therapeutic effects in cases of pituitary metastasis","volume":"117","author":"Zhao Y","year":"2018","unstructured":"Zhao Y, Lian W, Xing B,  Diagnosis, therapy, and therapeutic effects in cases of pituitary metastasis. World Neurosurg. 2018;117:122\u2013128.29883826"},{"issue":"4","key":"b5","series-title":"J Neurosurg","first-page":"998","article-title":"Pituitary metastases: current practice in Japan","volume":"123","author":"Habu M","year":"2015","unstructured":"Habu M, Tokimura H, Hirano H,  Pituitary metastases: current practice in Japan. J Neurosurg. 2015;123(4):998\u20131007.26186025"},{"issue":"2","key":"b6","series-title":"World Neurosurg","first-page":"327","article-title":"Pituitary metastases: role of surgery","volume":"79","author":"Zoli M","year":"2013","unstructured":"Zoli M, Mazzatenta D, Faustini-Fustini M, Pasquini E, Frank G. Pituitary metastases: role of surgery. World Neurosurg. 2013;79(2):327\u2013330.22480977"},{"issue":"1","key":"b7","series-title":"J Neurosurg","first-page":"69","article-title":"Symptomatic pituitary metastases","volume":"89","author":"Morita A","year":"1998","unstructured":"Morita A, Meyer FB, Laws ER Jr. Symptomatic pituitary metastases. J Neurosurg. 1998;89(1):69\u201373.9647174"},{"issue":"1","key":"b8","series-title":"J Neurol Neurosurg Psychiatry","first-page":"44","article-title":"Presentation and management of parasellar and suprasellar metastatic mass lesions","volume":"48","author":"Kattah JC","year":"1985","unstructured":"Kattah JC, Silgals RM, Manz H, Toro JG, Dritschilo A, Smith FP. Presentation and management of parasellar and suprasellar metastatic mass lesions. J Neurol Neurosurg Psychiatry. 1985;48(1):44\u201349.3973620"},{"issue":"4","key":"b9","series-title":"Neurosurg Focus","first-page":"E8","article-title":"Metastases to the pituitary gland","volume":"16","author":"Fassett DR","year":"2004","unstructured":"Fassett DR, Couldwell WT. Metastases to the pituitary gland. Neurosurg Focus. 2004;16(4):E8."},{"issue":"8","key":"b10","series-title":"Neurology","first-page":"998","article-title":"Pituitary metastasis: incidence in cancer patients and clinical differentiation from pituitary adenoma","volume":"31","author":"Max MB","year":"1981","unstructured":"Max MB, Deck MD, Rottenberg DA. Pituitary metastasis: incidence in cancer patients and clinical differentiation from pituitary adenoma. Neurology. 1981;31(8):998\u20131002.7196526"},{"issue":"5","key":"b11","series-title":"J Clin Endocrinol Metab","first-page":"1812","article-title":"Pituitary stalk lesions: the Mayo Clinic experience","volume":"98","author":"Turcu AF","year":"2013","unstructured":"Turcu AF, Erickson BJ, Lin E,  Pituitary stalk lesions: the Mayo Clinic experience. J Clin Endocrinol Metab. 2013;98(5):1812\u20131818."},{"issue":"1","key":"b12","series-title":"Radiology","first-page":"181","article-title":"Screening for cerebral metastases with FDG PET in patients undergoing whole-body staging of non-central nervous system malignancy","volume":"226","author":"Rohren EM","year":"2003","unstructured":"Rohren EM, Provenzale JM, Barboriak DP, Coleman RE. Screening for cerebral metastases with FDG PET in patients undergoing whole-body staging of non-central nervous system malignancy. Radiology. 2003;226(1):181\u2013187.12511688"},{"key":"b13","series-title":"American Cancer Society","article-title":"Lung cancer survival rates","unstructured":"Lung cancer survival rates. American Cancer Society. Updated March 2, 2022. Accessed February 21, 2023.https:\/\/www.cancer.org\/cancer\/lung-cancer\/detection-diagnosis-staging\/survival-rates.html"},{"key":"b14","series-title":"FDA.gov","article-title":"FDA approves durvalumab for extensive-stage small cell lung cancer","unstructured":"FDA approves durvalumab for extensive-stage small cell lung cancer. FDA.gov. Updated March 30, 2020. Accessed June 22, 2023.https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-durvalumab-extensive-stage-small-cell-lung-cancer"},{"issue":"1","key":"b15","series-title":"Lancet Oncol","first-page":"51","article-title":"Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial","volume":"22","author":"Goldman JW","year":"2021","unstructured":"Goldman JW, Dvorkin M, Chen Y,  Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2021;22(1):51\u201365.33285097"},{"issue":"3","key":"b16","series-title":"Lancet Oncol","first-page":"239","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell R","year":"2012","unstructured":"Rosell R, Carcereny E, Gervais R,  Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13(3):239\u2013246.22285168"},{"key":"b17","series-title":"Genentech","article-title":"FDA approves first personalized medicine for egfr mutation-positive metastatic non-small cell lung cancer in the United States","unstructured":"FDA approves first personalized medicine for egfr mutation-positive metastatic non-small cell lung cancer in the United States. Genentech. Updated March 14, 2013. Accessed June 22, 2023.https:\/\/www.gene.com\/media\/news-features\/tarceva-approval-nsclc#:~:text=May%2014th%2C%202013,by%20an%20FDA%2Dapproved%20test"},{"issue":"20","key":"b18","series-title":"Clin Cancer Res","first-page":"5130","article-title":"Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity","volume":"22","author":"Ballard P","year":"2016","unstructured":"Ballard P, Yates JW, Yang Z,  Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity. Clin Cancer Res. 2016;22(20):5130\u20135140.27435396"},{"key":"b19","series-title":"FDA.gov","article-title":"FDA approves osimertinib as adjuvant therapy for non-small cell lung cancer with EGFR mutations","unstructured":"FDA approves osimertinib as adjuvant therapy for non-small cell lung cancer with EGFR mutations. FDA.gov. Updated December 18, 2020. Accessed June 22, 2023.https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-osimertinib-adjuvant-therapy-non-small-cell-lung-cancer-egfr-mutations"},{"issue":"2","key":"b20","series-title":"N Engl J Med","first-page":"113","article-title":"Osimertinib in untreated EGFR-mutated advanced non\u2013small-cell lung cancer","volume":"378","author":"Soria JC","year":"2018","unstructured":"Soria JC, Ohe Y, Vansteenkiste J,  Osimertinib in untreated EGFR-mutated advanced non\u2013small-cell lung cancer. N Engl J Med. 2018;378(2):113\u2013125.29151359"},{"issue":"32","key":"b21","series-title":"J Clin Oncol","first-page":"3259","article-title":"National Cancer Institute Breast Cancer Steering Committee Working Group Report on Meaningful and Appropriate End Points for Clinical Trials in Metastatic Breast Cancer","volume":"36","author":"Seidman AD","year":"2018","unstructured":"Seidman AD, Bordeleau L, Fehrenbacher L,  National Cancer Institute Breast Cancer Steering Committee Working Group Report on Meaningful and Appropriate End Points for Clinical Trials in Metastatic Breast Cancer. J Clin Oncol. 2018;36(32):3259\u20133268."},{"issue":"12","key":"b22","series-title":"PLoS Med","first-page":"e1002201","article-title":"Mutational profile of metastatic breast cancers: a retrospective analysis","volume":"13","author":"Lefebvre C","year":"2016","unstructured":"Lefebvre C, Bachelot T, Filleron T,  Mutational profile of metastatic breast cancers: a retrospective analysis. PLoS Med. 2016;13(12):e1002201.28027327"},{"issue":"1","key":"b23","series-title":"NPJ Breast Cancer","first-page":"80","article-title":"Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups","volume":"7","author":"Johnston S","year":"2021","unstructured":"Johnston S, O\u2019Shaughnessy J, Martin M,  Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups. NPJ Breast Cancer. 2021;7(1):80.34158513"},{"key":"b24","article-title":"FDA approves new treatment for certain advanced or metastatic breast cancers","unstructured":"FDA approves new treatment for certain advanced or metastatic breast cancers. Accessed June 22, 2023.https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-treatment-certain-advanced-or-metastatic-breast-cancers"},{"key":"b25","series-title":"National Cancer Institute","article-title":"Breast cancer treatment (PDQ\u00ae)\u2013Health professional version","unstructured":"Breast cancer treatment (PDQ\u00ae)\u2013Health professional version. National Cancer Institute. Accessed June 22, 2023.https:\/\/www.cancer.gov\/types\/breast\/hp\/breast-treatment-pdq#_1452"},{"issue":"7","key":"b26","series-title":"N Engl J Med","first-page":"597","article-title":"Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer","volume":"382","author":"Murthy RK","year":"2020","unstructured":"Murthy RK, Loi S, Okines A,  Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med. 2020;382(7):597\u2013609.31825569"},{"key":"b27","series-title":"Drugs.com","article-title":"FDA approves Sutent for gastrointestinal stromal tumors and advanced renal cell carcinoma","unstructured":"FDA approves Sutent for gastrointestinal stromal tumors and advanced renal cell carcinoma. Drugs.com. Updated January 2006. Accessed June 22, 2023.https:\/\/www.drugs.com\/newdrugs\/fda-approves-sutent-gastrointestinal-stromal-tumors-advanced-renal-cell-carcinoma-389.html"},{"issue":"6C","key":"b28","series-title":"Anticancer Res","first-page":"4255","article-title":"Brain metastasis in renal cell cancer responding to sunitinib","volume":"27","author":"Koutras AK","year":"2007","unstructured":"Koutras AK, Krikelis D, Alexandrou N, Starakis I, Kalofonos HP. Brain metastasis in renal cell cancer responding to sunitinib. Anticancer Res. 2007;27(6C):4255\u20134257.18214028"},{"key":"b29","series-title":"FDA.gov","article-title":"FDA approves nivolumab plus cabozantinib for advanced renal cell carcinoma","unstructured":"FDA approves nivolumab plus cabozantinib for advanced renal cell carcinoma. FDA.gov. Updated January 22, 2021. Accessed June 22, 2023.https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-nivolumab-plus-cabozantinib-advanced-renal-cell-carcinoma"},{"issue":"9","key":"b30","series-title":"N Engl J Med","first-page":"829","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri TK","year":"2021","unstructured":"Choueiri TK, Powles T, Burotto M,  Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2021;384(9):829\u2013841.33657295"},{"issue":"14","key":"b31","series-title":"N Engl J Med","first-page":"1289","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer R","year":"2021","unstructured":"Motzer R, Alekseev B, Rha SY,  Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med. 2021;384(14):1289\u20131300."},{"key":"b32","series-title":"FDA.gov","article-title":"FDA approves lenvatinib plus pembrolizumab for advanced renal cell carcinoma","unstructured":"FDA approves lenvatinib plus pembrolizumab for advanced renal cell carcinoma. FDA.gov. Updated August 11, 2021. Accessed June 22, 2023.https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-lenvatinib-plus-pembrolizumab-advanced-renal-cell-carcinoma"},{"issue":"11","key":"b33","series-title":"Head Neck","first-page":"2407","article-title":"Survival and prognosis of metastatic head and neck adenoid cystic carcinoma","volume":"44","author":"Zhang D","year":"2022","unstructured":"Zhang D, Chai Y, Wei Y, Qi F, Dong M. Survival and prognosis of metastatic head and neck adenoid cystic carcinoma. Head Neck. 2022;44(11):2407\u20132416.35822446"},{"issue":"8","key":"b34","series-title":"Int J Oral Maxillofac Surg","first-page":"923","article-title":"Clinicopathological study of distant metastases of salivary adenoid cystic carcinoma","volume":"42","author":"Gao M","year":"2013","unstructured":"Gao M, Hao Y, Huang MX,  Clinicopathological study of distant metastases of salivary adenoid cystic carcinoma. Int J Oral Maxillofac Surg. 2013;42(8):923\u2013928.23706387"},{"issue":"35","key":"b35","series-title":"Oncotarget","first-page":"37117","article-title":"Adenoid cystic carcinoma: current therapy and potential therapeutic advances based on genomic profiling","volume":"6","author":"Chae YK","year":"2015","unstructured":"Chae YK, Chung SY, Davis AA,  Adenoid cystic carcinoma: current therapy and potential therapeutic advances based on genomic profiling. Oncotarget. 2015;6(35):37117\u201337134.26359351"},{"key":"b36","series-title":"Cancer.net","article-title":"Thyroid cancer: statistics","unstructured":"Thyroid cancer: statistics. Cancer.net. Updated March, 2022. Accessed June 22, 2023.https:\/\/www.cancer.net\/cancer-types\/thyroid-cancer\/statistics#:~:text=If%20there%20is%20distant%20spread,%2C%20the%20rate%20is%2063%25"},{"key":"b37","series-title":"Cancer Current Events Blog","article-title":"FDA approves lenvatinib for radioactive iodine-refractory thyroid cancer","unstructured":"FDA approves lenvatinib for radioactive iodine-refractory thyroid cancer. Cancer Current Events Blog. National Cancer Institute. March 2, 2015. Accessed June 22, 2023.https:\/\/www.cancer.gov\/news-events\/cancer-currents-blog\/2015\/fda-approves-lenvima"},{"issue":"10","key":"b38","series-title":"J Natl Cancer Inst","first-page":"1021","article-title":"The Molecular Analysis for Therapy Choice (NCI-MATCH) trial: lessons for genomic trial design","volume":"112","author":"Flaherty KT","year":"2020","unstructured":"Flaherty KT, Gray R, Chen A,  The Molecular Analysis for Therapy Choice (NCI-MATCH) trial: lessons for genomic trial design. J Natl Cancer Inst. 2020;112(10):1021\u20131029.31922567"}],"container-title":["Neurosurgical Focus"],"original-title":[],"link":[{"URL":"https:\/\/thejns.org\/view\/journals\/neurosurg-focus\/55\/2\/article-pE13.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/thejns.org\/downloadpdf\/journals\/neurosurg-focus\/55\/2\/article-pE13.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/thejns.org\/downloadpdf\/journals\/neurosurg-focus\/55\/2\/article-pE13.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T08:23:04Z","timestamp":1779524584000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejns.org\/view\/journals\/neurosurg-focus\/55\/2\/article-pE13.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":76,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.3171\/2023.5.focus23185","relation":{},"ISSN":["1092-0684"],"issn-type":[{"value":"1092-0684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8]]}}}